+81.2%
QBTS vs GSK
+46.9%
+34.4%
-96.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.6% | -2.7% | +9.3% | +6.7% |
| 7D | +6.8% | -4.2% | +11.0% | +7.1% |
| 30D | -14.9% | -7.5% | -7.4% | -14.4% |
| 3M | -31.6% | -3.3% | -28.3% | -31.6% |
| 6M | -4.9% | -9.3% | +4.4% | -4.4% |
| YTD | -32.4% | +1.6% | -34.0% | -33.1% |
| 1Y | +14.6% | +25.5% | -10.9% | +9.8% |
| 3Y | +1,839.6% | +49.3% | +1,790.4% | +1,711.3% |
| 5Y | +81.2% | +46.7% | +34.6% | +79.2% |
| All | +81.2% | +46.9% | +34.4% | +79.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling